Sanofi-Aventis SA and Genzyme Corp. have reached an agreement in principle under which Sanofi will acquire Genzyme for $74 a share in cash plus a right to future payments based on the performance of Genzyme’s experimental multiple sclerosis drug, according to a source with knowledge of the discussions.

The deal is expected to be announced by Wednesday morning, the source said.